Funding
← Back to your selection

Soleus Capital

Activity from announced rounds

Activity in this selectionOct 20, 2026 · Jul 23, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$176M
2 disclosed · full round size, not this investor’s share

By stage

Series C+1
Undisclosed1

By primary sector

Biotech1
Healthtech1

By country

United States2

Rounds

2 in this selection
Abcuro

Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.

$66MSeries D
Role not disclosed
Bridge to Life

Makes organ preservation and perfusion technology for liver transplants

$110MSeries C+Debt
Role not disclosed